NIH PAR · NIAMS · R61
PAR-24-279: Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required) PAR, a re-issue of PAR-24-035, was re-issued as a result of the Simplifying Review of Research Project Grant Applications [link: https://grants.nih.gov/policy-and-compliance/policy-topics/peer-review/simplifying-review]. The Simplify Review changes in Section V are the only changes that have been made. All other aspects of this funding opportunity remain the same.
- NOFO number
- PAR-24-279
- Type
- PAR
- Activity code
- R61
- Primary institute
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Clinical trials
- Required
- Posted
- Dec 9, 2024
- Opens
- Feb 4, 2025
- Expires
- Nov 3, 2026
PAR-24-279 due dates
1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| March 04, 2025 | March 04, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| July 02, 2025 | July 02, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| November 04, 2025 | November 04, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| March 04, 2026 | March 04, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| July 02, 2026 | July 02, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| November 02, 2026 | November 02, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
Projects funded under PAR-24-279
NIH RePORTER lists 3 projects funded under PAR-24-279 in FY2022–FY2026, with $1.5M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$1.5M
Award dollars under PAR-24-279, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 3 | 3 | $1.5M |
Institutions with the most funding
- Univ of Massachusetts Med Sch Worcester$975K · 1 project
- Stanford University$302K · 1 project
- Massachusetts General Hospital$228K · 1 project
Funding institutes
- NIAMS$1.5M · 3
Activity codes funded
- R613 records
Most recent new awards
- Topical Statin Therapy for Proliferating Infantile Hemangioma (opens NIH RePORTER)
Stanford University · 1R61AR088483-01 · NIAMS · Notice Sep 17, 2026
$302KR61
- Botulinum toxin blockade of neuronal signals to immune cells as a novel treatment for hidradenitis suppurativa (opens NIH RePORTER)
Univ of Massachusetts Med Sch Worcester · 1R61AR087105-01A1 · NIAMS · Notice Sep 11, 2026
$975KR61
- Toward Biomarker-Guided Fibromyalgia Treatment with Non-Invasive Vagus Nerve Stimulation (opens NIH RePORTER)
Massachusetts General Hospital · 1R61AR086955-01A1 · NIAMS · Notice Sep 4, 2026
$228KR61
What its predecessor PAR-24-035 funded
PAR-24-279 reissues PAR-24-035. Its funding history is the best guide to who wins under this program: 2 projects and $1.1M in FY2022–FY2026.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$1.1M
Award dollars under PAR-24-035, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 2 | 2 | $559K |
| FY2026 | 2 | 0 | $528K |
Institutions with the most funding
- Tufts Medical Center$639K · 1 project
- Massachusetts General Hospital$448K · 1 project
Funding institutes
- NIAMS$1.1M · 4
Activity codes funded
- R614 records
Most recent new awards
- Veverimer to decrease net acid excretion and bone resorption in adults with osteopenia: a dose-finding randomized controlled trial (opens NIH RePORTER)
Tufts Medical Center · 1R61AR085647-01 · NIAMS · Notice Jul 31, 2025
$331KR61
- SGLT2i As Novel Gout Care (SAVE-Care): A Randomized Controlled Trial (opens NIH RePORTER)
Massachusetts General Hospital · 1R61AR084188-01A1 · NIAMS · Notice Jun 18, 2025
$228KR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-24-279. Contact the program officer at the institute that fits your research before applying.
- NIAMS · National Institute of Arthritis and Musculoskeletal and Skin Diseases
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 3 NOSIs to PAR-24-279; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- The combined budget for direct costs for the three-year period may not exceed 600,000. No more than 300,000 direct costs may be requested in any single year. 
- Project period
- The scope of the proposed project should determine the project period. The maximum project period is three years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-035.
Other open NOFOs for R61
- PAR-27-045HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)NCCIH · next due Oct 30, 2026
- RFA-AI-27-018Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)NIAID · next due Nov 10, 2026
- RFA-NS-25-023HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)NINDS · next due Jan 15, 2027
- RFA-OD-27-005INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)OD · next due Jun 15, 2027
- PAR-25-158Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)NIAAA · next due Oct 19, 2026
- PAR-25-269NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)NCCIH · next due Oct 20, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.